Reasons for the Lack of Salutary Effects of Cholesterol-Lowering Interventions in End-Stage Renal Disease Populations

Publisher： Karger

E-ISSN： 1421-9735|35|1-3|31-36

ISSN： 0253-5068

Source： Blood Purification, Vol.35, Iss.1-3, 2013-01, pp. : 31-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

C-Reactive Protein in End-Stage Renal Disease: Are There Reasons to Measure It?

By  

Blood Purification, Vol. 23, Iss. 1, 2011-02 ,pp. : 72-78

Karger

Access to resources Recommend Favorite

Keloids and End-Stage Renal Disease

By  

Nephron, Vol. 80, Iss. 2, 1998-09 ,pp. : 244-246

Karger

Access to resources Recommend Favorite

Effects of Hemodialysis on Circulating Adrenomedullin Concentrations in Patients with End-Stage Renal Disease

By  

Blood Purification, Vol. 16, Iss. 5, 1999-01 ,pp. : 269-274

Karger

Access to resources Recommend Favorite

Lack of Serologic Evidence for an Association between Hantavirus Infection and End-Stage Renal Disease

By  

Nephron, Vol. 80, Iss. 1, 1998-09 ,pp. : 93-93

Karger

Access to resources Recommend Favorite

Marked Atherosclerosis in a Patient with Familiar Lecithin: Cholesterol Acyltransferase Deficiency Associated with End-Stage Renal Disease and Diabetes Mellitus

By  

American Journal of Nephrology, Vol. 21, Iss. 5, 2001-10 ,pp. : 415-419

Karger

Access to resources Recommend Favorite